Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.

Sponsor
QIAO LI
Study ID
NCT06857747
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Capecitabine — DRUG
    metronomic capecitabine, 500 mg, tid， po
  • Vinorelbine — DRUG
    metronomic vinorelbine, 40mg/d, TIW1, po
  • Etoposide — DRUG
    metronomic etoposide, 50mg/d, po

Study Details

This study aims to explore the efficacy of Disitamab vedotin in combination with metronomic chemotherapy in advanced breast cancer. By integrating the rapid onset of action of Disitamab vedotin with the characteristics of metronomic chemotherapy, the study seeks to further improve patients' response rates and enhance their quality of life, building upon the extension of patient survival.

Key Dates

Start date
Mar 1, 2025
Status verified
Mar 2024
Primary completion
Dec 1, 2025
Completion
Apr 1, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: HER2-positive advanced breast cancer
    Patients will receive disitamab vedotin combining with metronomic chemotherapy in a 3-week treatment cycle.
  • Experimental: HER2 2+/1+ expressed in IHC advanced breast cancer
    Patients will receive disitamab vedotin combining with metronomic chemotherapy in a 3-week treatment cycle.

Primary Outcome Measure

Progression-free survival，PFS [ Time Frame: 21 or 28 days after the last dose ]

Central Contacts

Related Studies